Costa Mesa-based Oxygen Biotherapeutics is contracting with the Naval Medical Research Center and the Walter Reed Army Institute of Research to study Oxycyte in the treatment of decompression sickness and arterial gas embolism.
Under the Limited Purpose Cooperative Research and Development Agreement, the two Department of Defense laboratories hope to formally begin testing whether Oxycyte, a perfluorocarbon therapeutic oxygen carrier that's designed to enhance oxygen delivery to damaged tissues, is safe and effective for therapy. If the results are positive, the agency will submit an application to the Food and Drug Administration for approval of Oxycyte in humans.
Oxygen will provide information to the agencies for use in these tests but will retain ownership of the intellectual property, according to company Chairman and CEO Chris Stern.
NEXT PAGE >>
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCo may gauge asthma severity in kids
May is Huntington's Disease Awareness month
UC Irvine Medical Center lands stroke therapy center designation